Status:
COMPLETED
Perioperative Dexamethasone on Postoperative Outcome in IBD
Lead Sponsor:
Jinling Hospital, China
Conditions:
Inflammatory Bowel Diseases
Dexamethasone
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The objective of this RCT is to determine the efficacy of a single preoperative dose of Dexamethasone for accelerating the recovery and reducing the incidence of postoperative complications in adult p...
Detailed Description
Patients undergoing surgery for IBD is associated with increased inflammatory response and incidence of prolonged ileus after surgery compared to other colorectal disease such as CRC. Previous studies...
Eligibility Criteria
Inclusion
- Patients undergoing elective open and laparoscopic small and large bowel operations for IBD, including Crohn's Disease(CD) and Ulcerative Colitis (UC).
- ASA I-III
Exclusion
- Diabetes or hyperglycemia
- Active gastric ulceration confirmed endoscopically
- Presence of ongoing infection (such as IAS) or infective chronic diseases
- Currently receiving systemic therapy with glucocorticoids with prednisolone \>=20mg for over 6 weeks within 30 days prior to surgery.
- Emergent surgery
- Acute angle glaucoma
- Pregnancy
- Under 18 years of age
- Known adverse reaction to dexamethasone
- Extensive adhesiolysis
- Carcinogenesis of intestinal tract
Key Trial Info
Start Date :
June 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 13 2020
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT03456752
Start Date
June 1 2018
End Date
January 13 2020
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Generay Surgery, Jinling hosptal, Medical School of Nanjing University
Nanjing, Jiangsu, China, 210000